FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Saturday

 

Visual Assessment May Provide Information on Cognitive Function in MS Patients




























Researchers at Johns Hopkins University in Baltimore found that visual function in MS patients correlates with cognitive function ands suggests that disease severity and outcomes of neuroprotective therapies in MS patients may be assessed through visual function measurements.

The findings were recently presented in the oral presentation “Anterior Visual Pathway Measures Are Strongly Associated with Cognitive Function in Multiple Sclerosis,” during the June 1-4 Consortium of Multiple Sclerosis Centers (CMSC) 2016 Annual Meeting, in Maryland.

Optical coherence tomography (OCT) is a noninvasive diagnostic tool that uses near infrared light to provide cross-sectional images of the retinal architecture, which enables the quantitative measurement of retinal conditions, such as ganglion cell and inner plexiform layer (GCIP) thickness.

It is known that in MS patients, GCIP thickness is associated with visual function, gray matter volume, and disability, as measured by the Expanded Disability Status Scale (EDSS) scores. Whether GCIP thickness and visual function are related to cognitive function had been unknown to date.

Researchers aimed to unravel GCIP thickness and visual function correlated with cognitive measures.

The study enrolled 130 participants, 97 of whom had relapsing-remitting MS (RRMS), and 33 had progressive MS. Patients were subjected to OCT and a contrast letter acuity test; cognitive function was assessed through Multiple Sclerosis Functional Composite (MSFC), California Verbal Learning Test-II (CVLT-II), Single Digit Modalities Test (SDMT), and Brief Visuospatial Memory Test-Revised (BVMT-R).

Results demonstrated that patients with RRMS, but not progressive MS, exhibited significant associations between GCIP thickness and both MSFC and BVMT-R scores. Similarly, contrast letter acuity test scores were also associated with MSFC and BVMT-R scores in RRMS, but not progressive MS. The associations were restricted to patients without a history of optic neuritis, a demyelinating inflammation of the optic nerve.

The results suggested that the anterior visual pathway function is associated with cognitive function in MS patients. In RRMS patients without a history of optic neuritis, GCIP thickness and contrast letter acuity scores may prove to be useful tools in the measurement of global disease aspects, and in providing information on the outcomes of neuroprotective therapies in clinical trials for patients with MS.

Story Source: The above story is based on materials provided by MULTIPLESCLEROSISNEWSTODAY
Note: Materials may be edited for content and length

Labels:



Go to Newer News Go to Older News